For years, approved ruxolitinib cream has stopped at age 12. Younger children have had a much shorter menu: steroids, tacrolimus, light therapy if you can get a slot, and a lot of waiting.

Now two Phase III studies are evaluating ruxolitinib cream in younger children. Its use for vitiligo in these age groups is investigational — researchers are still finding out how well it works and how safe it is. Real protocols. Real sites. Not a rumor from a parent group.

Then the catch: they are not the same study. Mix them up and a family books the wrong continent.

In this episode of Deep Dive in Vitiligo, we put the trials side by side.

You’ll hear:

• North American trial TRuE-ViP (NCT06548360) — ages 2 to 11, United States and Canada
• The international trial (NCT06804811, Incyte INCB18424-309) — starts at age 6, Argentina plus 13 European countries, no U.S. or Canadian sites
• What they share: nonsegmental vitiligo, a 10% body-surface ceiling, active-versus-vehicle treatment during the first 24 weeks, facial scoring at Week 24, and some restrictions.
• Why an 8-year-old can fit both studies by age and neither by postcode.

Do not stop a working routine because two trial pages appeared in the same week. Ask the site what would pause. Then call the child’s regular dermatologist.

Yes is a reasonable answer. No is a reasonable answer. The useful question is which protocol — if either — fits this child, in this country, with this schedule.

Both studies discussed in this episode are sponsored by Incyte Corporation. VRF provides patient education and study-awareness support related to Incyte pediatric vitiligo research under a paid services agreement. VRF does not determine study eligibility or recommend participation.

📚 Prefer reading to listening? These two companion articles expand on many of the themes discussed in this episode.

• Vitiligo Study For Children Ages 2–11 in USA and Canada 
• Vitiligo Study For Children Ages 6-11, International